Design and protocol for the Focusing on Clozapine Unresponsive Symptoms (FOCUS) trial: a randomised controlled trial

BACKGROUND: For around a third of people with a diagnosis of schizophrenia, the condition proves to respond poorly to treatment with many typical and atypical antipsychotics. This is commonly referred to as treatment-resistant schizophrenia. Clozapine is the only antipsychotic with convincing effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Pyle, Melissa, Norrie, John, Schwannauer, Matthias, Kingdon, David, Gumley, Andrew, Turkington, Douglas, Byrne, Rory, Syrett, Suzy, MacLennan, Graeme, Dudley, Robert, McLeod, Hamish J., Griffiths, Helen, Bowe, Samantha, Barnes, Thomas R. E., French, Paul, Hutton, Paul, Davies, Linda, Morrison, Anthony P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4974812/
https://www.ncbi.nlm.nih.gov/pubmed/27496180
http://dx.doi.org/10.1186/s12888-016-0983-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4974812/
https://www.ncbi.nlm.nih.gov/pubmed/27496180
http://dx.doi.org/10.1186/s12888-016-0983-6

Ejemplares similares